Latest News

About 35,000 people die from drug-resistant infection in the US. What are we going to do?
When antibiotics first achieved widescale use in the middle of the 20th century, they had a tremendous impact. For example, the mortality rate in England from infectious disease dropped from 25% in 1…
Read more
Nasal nanoSTING vaccines may Provide Lasting Protection Against SARS-CoV-2
All successful vaccines against SARS-CoV-2 have used the spike protein as the target and delivered the vaccine by intramuscular injection, typically a shot in the left or right shoulder. The vaccines…
Read more
Probiotic Bacterium can prevent antibiotic use side effects
Researchers at the University of Maryland School of Medicine demonstrate the power of probiotics. A test group was given Bifidobacterium lactis BB-12 as they took a course of amoxicillin clavula…
Read more
The CDC publishes another study that shows the protection that vaccination provides against COVID-19
The CDC is out with another recent study comparing the incidence rate of COVID-19 in unvaccinated vs. vaccinated individuals. It is mostly good news. The vaccine protects against infection, hospitali…
Read more
No, that is NOT what the study says -- Immunity to COVID
I am getting tired of the scare tactics that news and media sources are using to get you to click on headlines. Headlines in some press releases drive me bananas: New study: Nursing home residents,…
Read more

News

Finally, a potentially powerful treatment for COVID-19


 

At the present time, there are no blockbuster drugs that dramatically improve the outcome of patients infected with SARS-CoV-2. While remdesivir and steroids do improve time to recovery and mortality, neither reverse the course of disease in most patients, especially if the patient has waited too long to go to the hospital. One promising area of research is antibody treatments, where antibodies are created that attack the spike protein of SARS-CoV-2 and label it for destruction. The problem with these treatments is that they are expensive, heat-labile, and do not scale well.

 

Recently, Göttingen researchers have developed mini-antibodies, derived from alpacas, that solve all of these drawbacks. They bind extremely tightly to the spike protein, are cheaper to produce, can be made in large quantities, and are stable up to 95°C (that is close to the temperature of boiling water). Their heat stability is especially useful as it makes it much easier to distribute and administer the antibodies. Their new drug is about to enter clinical trials and here is hoping that it turns out to be a powerful weapon against SARS-CoV-2.